Key result
Botulinum toxin injection into epicardial fat pads during CABG reduced early postoperative AF and recurrent AF at 1 year compared to placebo.
Why the study?
Does botulinum toxin injection into epicardial fat pads prevent atrial fibrillation in patients with paroxysmal atrial fibrillation undergoing coronary artery bypass graft surgery?
RCT (n=60)
Double-blind
randomized
Does botulinum toxin injection into epicardial fat pads prevent atrial fibrillation in patients with paroxysmal atrial fibrillation undergoing coronary artery bypass graft surgery?
Botulinum toxin injection into epicardial fat pads during CABG significantly suppressed both early postoperative and 1-year recurrent atrial fibrillation without serious adverse events.
Answers are grounded in this paper and cite their sources.
Supports epicardial botulinum toxin injection during CABG for paroxysmal AF; extends neuromodulation evidence for postoperative AF prevention.
BACKGROUND: Animal models suggest that the neurotransmitter inhibitor, botulinum toxin, when injected into the epicardial fat pads can suppress atrial fibrillation inducibility. The aim of this prospective randomized double-blind study was to compare the efficacy and safety of botulinum toxin injection into epicardial fat pads for preventing atrial tachyarrhythmias. METHODS AND RESULTS: Patients with history of paroxysmal atrial fibrillation and indication for coronary artery bypass graft surgery were randomized to botulinum toxin (Xeomin, Merz, Germany; 50 U/1 mL at each fat pad; n=30) or placebo (0.9% normal saline, 1 mL at each fat pad; n=30) injection into epicardial fat pads during surgery. Patients were followed for 1 year to assess maintenance of sinus rhythm using an implantable loop recorder. All patients in both groups had successful epicardial fat pad injections without complications. The incidence of early postoperative atrial fibrillation within 30 days after coronary artery bypass graft was 2 of 30 patients (7%) in the botulinum toxin group and 9 of 30 patients (30%) in the placebo group (P=0.024). Between 30 days and up to the 12-month follow-up examination, 7 of the 30 patients in the placebo group (27%) and none of the 30 patients in the botulinum toxin group (0%) had recurrent atrial fibrillation (P=0.002). There were no complications observed during the 1-year follow-up. CONCLUSIONS: Botulinum toxin injection into epicardial fat pads during coronary artery bypass graft provided substantial atrial tachyarrhythmia suppression both early as well as during 1-year follow-up, without any serious adverse events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01842529.
No takes yet. Share an insight, caveat, or question.
Pokushalov et al. (2015) conducted an RCT in Paroxysmal atrial fibrillation (n=60). Botulinum toxin vs. Placebo (0.9% normal saline, 1 mL at each fat pad) was evaluated on Early postoperative atrial fibrillation within 30 days (p=0.024). Botulinum toxin injection into epicardial fat pads during CABG reduced early postoperative AF and recurrent AF at 1 year compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: